 |
23 Diseases |  |
162 Trials |
|
162 Trials |  |
4758 News |  |
| «12...49505152535455565758596061 |
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease (clinicaltrials.gov) - Oct 27, 2013
P1, N=48, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) (clinicaltrials.gov) - Oct 20, 2013
P3, N=787, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Sep 16, 2013
P1, N=70, Recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting Suspended --> Recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial initiation date: An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 25, 2013
P4, N=0, Approved for marketing, Sponsor: Genentech
Suspended --> Recruiting Initiation date: May 2013 --> Aug 2013
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Biomarker, Enrollment closed, Combination therapy, Metastases: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) (clinicaltrials.gov) - Aug 25, 2013
P2, N=100, Active, not recruiting, Sponsor: Genentech
Initiation date: May 2013 --> Aug 2013 Recruiting --> Active, not recruiting
- ||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Combination therapy: A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 13, 2013
P1, N=70, Recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting Suspended --> Recruiting
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P3 trial, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jul 21, 2013
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
New P2 trial: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 26, 2013
P2, N=150, Recruiting, Sponsor: PrECOG, LLC.
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P4 trial: An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jun 3, 2013
P4, N=0, Approved for marketing, Sponsor: Genentech
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Monotherapy: GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 22, 2013
P2, N=197, Completed, Sponsor: Hoffmann-La Roche
Suspended --> Recruiting Active, not recruiting --> Completed
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma (clinicaltrials.gov) - Jan 8, 2013
P1/2, N=200, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) (clinicaltrials.gov) - Nov 11, 2012
P2, N=80, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial initiation date: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma (clinicaltrials.gov) - Oct 1, 2012
P1/2, N=200, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Recruiting --> Active, not recruiting Initiation date: Jun 2012 --> Oct 2012
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, Enrollment open: GAINED: GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Sep 30, 2012
P3, N=670, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Initiation date: Jun 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- ||||| New P2 trial, Combination therapy: ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov) - Sep 23, 2012
P2, N=124, Active, not recruiting, Sponsor: Genentech
- ||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P1 trial, Combination therapy: A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 12, 2012
P1, N=70, Recruiting, Sponsor: Genentech
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P1 trial: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease (clinicaltrials.gov) - Sep 5, 2012
P1, N=48, Active, not recruiting, Sponsor: Hoffmann-La Roche
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed, Combination therapy: A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON) (clinicaltrials.gov) - Aug 27, 2012
P1, N=41, Active, not recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change, Combination therapy: A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Aug 23, 2012
P1, N=70, Recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting N=7070 --> 70
- ||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P1 trial, Combination therapy: A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Aug 22, 2012
P1, N=70, Recruiting, Sponsor: Genentech
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, New P3 trial: GAINED: GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Aug 5, 2012
P3, N=670, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
- ||| New P1 trial, Combination therapy: Phase 1b Safety and Efficacy Study of TRU-016 (clinicaltrials.gov) - Jul 17, 2012
P1, N=56, Active, not recruiting, Sponsor: Emergent Product Development Seattle LLC
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P1/2 trial: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma (clinicaltrials.gov) - Apr 19, 2012
P1/2, N=200, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial initiation date, Combination therapy: A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON) (clinicaltrials.gov) - Mar 20, 2012
P1, N=41, Active, not recruiting, Sponsor: Genentech
N=7070 --> 70 Initiation date: Mar 2011 --> Jun 2011
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Biomarker, New P2 trial, Combination therapy, Metastases: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) (clinicaltrials.gov) - Aug 9, 2011
P2, N=100, Active, not recruiting, Sponsor: Genentech
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) (clinicaltrials.gov) - Aug 9, 2011
P2, N=80, Active, not recruiting, Sponsor: Genentech
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) (clinicaltrials.gov) - Aug 9, 2011
P3, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Mar 2011 --> Jun 2011 Not yet recruiting --> Recruiting